Ycyst M Tablet is a combination oral medication containing Metformin 500 mg and Alpha Lipoic Acid 200 mg, primarily indicated for the management of type 2 diabetes mellitus and associated diabetic neuropathy. Metformin, a biguanide antihyperglycemic agent, functions by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake, thereby effectively controlling blood glucose levels. Alpha Lipoic Acid, a potent antioxidant, plays a crucial role in reducing oxidative stress and improving nerve function, which is beneficial in mitigating symptoms of diabetic neuropathy such as pain, burning, and numbness. The synergistic effect of these two agents aids in achieving optimal glycemic control while providing neuroprotective benefits. Ycyst M Tablet is generally well-tolerated; however, it should be used with caution in patients with renal impairment, hepatic dysfunction, or metabolic acidosis. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, which are typically transient. Regular monitoring of blood glucose levels, renal function, and vitamin B12 status is recommended during therapy. This combination therapy should be prescribed as part of a comprehensive diabetes management plan, including diet, exercise, and lifestyle modifications, under the supervision of a healthcare professional.